NUCALA—the first anti-interleukin 5 (IL-5) that targets eosinophils across indications

Severe Eosinophilic Asthma

The first anti-IL-5 add-on treatment for severe asthma with an eosinophilic phenotype

LEARN MORE

EGPA
(Eosinophilic Granulomatosis With Polyangiitis)

The first anti-IL-5 treatment for EGPA (formerly Churg-Strauss syndrome)

LEARN MORE

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

 

1008962R0 September 2018

Chat